220602-61-9Relevant articles and documents
Pyridobenzodiazepines: A novel class of orally active, vasopressin V 2 receptor selective agonists
Failli, Amedeo A.,Shumsky, Jay S.,Steffan, Robert J.,Caggiano, Thomas J.,Williams, David K.,Trybulski, Eugene J.,Ning, Xiaoping,Lock, Yeungwai,Tanikella, Tarak,Hartmann, David,Chan, Peter S.,Park
, p. 954 - 959 (2007/10/03)
Our efforts in seeking low molecular weight agonists of the antidiuretic peptide hormone arginine vasopressin (AVP) have led to the identification of the clinical candidate WAY-151932 (VNA-932). Further exploration of the structural requirements for agonist activity has provided another class of potent, orally active, non-peptidic vasopressin V2 receptor selective agonists exemplified by the 5,11-dihydro-pyrido[2,3-b][1,5]benzodiazepine as a candidate for further development.
Tricyclic pyridine N-oxides vasopressin agonists
-
, (2008/06/13)
The present invention provides compounds of the general formula: as well as methods and pharmaceutical compositions utilizing these compounds for the inducement of temporary delay of urination or the treatment of disorders which may be remedied or alleviated by vasopressin agonist activity, including diabetes insipidus, nocturnal enuresis, nocturia, urinary incontinence, bleeding and coagulation disorders.
Tricyclic vasopressin agonists
-
, (2008/06/13)
The present invention provides compounds of the general formula: wherein W is O or NH, optionally substituted, as well as methods and pharmaceutical compositions utilizing these compounds for the treatment of disorder which may be remedied or alleviated by vasopressin agonist activity, including diabetes insipidus, nocturnal enuresis, nocturia, urinary incontinence, bleeding and coagulation disorders, or temporary delay of urination.